Lupus Foundation of America Statement on Results for Clinical Study
of CellCept Released by Aspreva Pharmaceutical Company
Statement by Sandra C. Raymond, President & CEO of the
LupusFoundation of America, Inc. WASHINGTON, June 27, 2007 /PRNewswire-USNewswire/ -- The
LupusFoundation of America, Inc. and more than 1.5 million Americanswith
lupus have been awaiting the preliminary findings of the PhaseIII clinical trials for CellCept(R), a potential treatment for
lupus kidney disease being tested by Aspreva...
Aspreva and Roche Announce Preliminary Results for Phase III Study
Evaluating CellCept in Lupus Nephritis
VICTORIA, BC, Canada and BASEL, Switzerland, June 27 /CNW/ -Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) andRoche today released preliminary results for a clinical trialcomparing CellCept (oral mycophenolate mofetil, MMF) to intravenouscyclophosphamide (IVC), which is the current standard of care, forinducing treatment response in the induction phase of patientssuffering fro...
Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B
Showed Significant Reductions in Disease Activity in Patients with
Active Systemic Lupus Erythematosus
-LymphoStat-B(R) significantly reduced signs and symptoms of SLEdisease at 52 Weeks and demonstrated durable clinical andbiological activity at 76 weeks- ROCKVILLE, Md., June 14, 2007 /PRNewswire-FirstCall/ -- HumanGenome Sciences, Inc. today announced the presentation of Phase 2trial data demonstrating that LymphoStat-B(R) (belimumab)significantly reduced disease activity across multiple...
Cellerant Therapeutics Reversed Autoimmune Disease in Lupus Mice
with Transplant of Purified Donor Blood Stem Cells
SAN CARLOS, Calif.--(BUSINESS WIRE)--Apr 23, 2007 - CellerantTherapeutics today announced the publication of data suggestingthat established autoimmune disease can be reversed or stabilizedby the transplantation of purified allogeneic (donated)hematopoietic (blood forming) stem cells (HSC) in a mouse study ofSystemic
Lupus Erythematosus (SLE). Subjects that underwent thisprocedure exhibited...
La Jolla Pharmaceutical Provides Update on Interim Antibody Results
From Riquent Lupus Phase 3 Trial
SAN DIEGO, March 20, 2007 /PRNewswire-FirstCall/ -- La JollaPharmaceutical Company today announced updated interim antibodyreduction data for the Phase 3 trial of Riquent(R) (abetimussodium), its drug candidate for systemic
lupus erythematosus("
lupus" or "SLE"). The updated analyses reinforce the previousconclusion that there is a definitive and significant dose responsebetween the 100 m...
La Jolla Pharmaceutical Announces Positive Interim Antibody Results
From Riquent Lupus Phase 3 Trial
Data Support Ability of Higher Doses to Further Reduce Antibodiesto Double-Stranded DNA SAN DIEGO, March 08, 2007 /PRNewswire-FirstCall/ -- La JollaPharmaceutical Company today announced positive interim antibodyresults from its ongoing double-blind, placebo-controlledrandomized Phase 3 trial of Riquent(R) (abetimus sodium), its drugcandidate for systemic
lupus erythematosus ("
lupus" or "...